Navigation Links
Data Presented at 49th EASD Annual Meeting Show Treatment with Lilly's Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
Date:9/26/2013

al diabetes molecules in Lilly's late-stage pipeline. The company has a number of potential new medicines in clinical development for the treatment of diabetes and its related conditions. Lilly expects to submit dulaglutide to regulatory authorities in 2013.

About the Study1,2
AWARD-1 was a randomised, 52-week, placebo-controlled comparison of the effects of dulaglutide and exenatide twice-daily on glycaemic control in patients with type 2 diabetes on metformin and pioglitazone. The primary objective of the study, conducted in 978 patients, was to evaluate whether dulaglutide 1.5 mg, dosed once-weekly, was superior to placebo in reducing HbA1c from baseline at 26 weeks.

To evaluate health outcomes, patients were administered questionnaires at baseline and again prior to follow-up visits at 26 and 52 weeks. Treatment satisfaction[*], as well as perceived hyperglycaemia and hypoglycaemia, were measured using the Diabetes Treatment Satisfaction Questionnaire (DTSQ); impact of weight was measured using the Impact of Weight on Self-Perception Questionnaire (IW-SP) and the Ability to Perform Physical Activities of Daily Living Questionnaire (APPADL); and perceived current health status was measured using the EuroQoL 5-Dimension Questionnaire (EQ-5D).

About Diabetes
Approximately 25.8 million Americans3 and an estimated 371 million people4 worldwide have type 1 and type 2 diabetes. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases. Diabetes is a chronic disease that occurs when the body either does not properly produce, or use, the hormone insulin.5

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and our cont
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
2. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
3. Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012
4. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
5. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
6. eCardios CEO to Speak During "Act at the Speed of Opportunity" Event Presented by Comcast Business Class and Inc.
7. CutisPharma Homogeneity and Stability Study for Mouthwash Compounding Kits Presented at NERDG Meeting
8. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
9. Webcast Alert: Isis Pharmaceuticals Hosts Dr. Sotirios Tsimikas to Review KYNAMRO™ data Presented at the European Atherosclerosis Society 2012 Meeting
10. Body Monitors Deliver Better Weight Loss Results at Half the Cost: Study to Be Presented at ACSM Meeting
11. CyberKnife® Prostate SBRT Outcomes and Quality of Life Data Presented at American Urological Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  BC Technical, the largest ... MiE America , Inc., a leading provider of Siemens ... a long-term agreement naming BC Technical as the authorized ... MiE and BC Technical announced today that ... establish BC Technical as the service and systems provider ...
(Date:7/10/2014)... July 10, 2014 CVS Caremark Corporation (NYSE: ... has approved a quarterly dividend of $0.275 (27.5 cents) per ... on August 1, 2014, to holders of record on July ... CVS Caremark is dedicated to helping people on their path ... the United States . Through the company,s ...
(Date:1/15/2014)... 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced ... Global Industry Analysis, Size, Share, Growth, Trends And Forecast, ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... patients in order to treat dental impairments, for tooth ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
... 25 BiPar Sciences, Inc., a,privately held ... molecular biomarker data demonstrating the overexpression,of the ... ovarian, breast and lung tumors. The research ... specific types of cancer. This,insight is being ...
... ... inhibitors, SAN FRANCISCO, ... the discovery, rapid,development and commercialization of therapies for solid tumors and,hematological ... the 2007 AACR-NCI-EORTC International Conference that,describe how its proprietary CLIMB technology ...
Cached Medicine Technology:BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types 2Data Support use of SuperGen's CLIMB Technology in Lead Development and Optimization 2Data Support use of SuperGen's CLIMB Technology in Lead Development and Optimization 3
(Date:7/11/2014)... Datalogic brings a new and innovative scanner ... With their new Gryphon GD4400 and GM4400 ... devastating MRSA, which claimed 5,500 lives, becomes more preventable. ... and the Gryphon GM4400-HC 2D readers can scan nearly ... barcodes off of troublesome LCD monitors, smartphones, and other ...
(Date:7/11/2014)... Boston, MA (PRWEB) July 11, 2014 ... save at least $50 billion in fuel ... effect immediately. The current GHG standards ... manufacturers have taken it upon themselves to ... they include: , 1.    Idle reduction technologies , ...
(Date:7/11/2014)... (HealthDay News) -- Children who have emergency surgery ... and potentially even death than those who have ... However, the Johns Hopkins researchers noted that the ... analyzed data on nearly 440,000 simple emergency surgeries ... a 22-year period. The surgeries are considered ...
(Date:7/11/2014)... Oakland, CA (PRWEB) July 11, 2014 Ticket ... tickets at the Concord Pavilion . When it comes to ... from Luke Bryan. The 37-year-old Georgia native is one of the ... in the entertainment business. Bryan is currently out on his “That’s ... Among the many stops the tour will be making through the ...
(Date:7/11/2014)... Alliance for Cancer Gene Therapy, ... exclusively to cell and gene therapies for cancer ... the organization as Senior Development Officer. , Corday ... securing gifts and addressing influential donors. Prior to ... for NewYork Presbyterian Hospital/Columbia University Medical Center, where ...
Breaking Medicine News(10 mins):Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3
... Bush,today visited the Maamobi Polyclinic in the Greater ... being implemented by AED to control,malaria., Through ... commercial,sector to increase the availability and affordability of ... and five,other sub-Saharan African countries, and is supported ...
... the recently,released Audit Bureau of Circulations FAS-FAX report, ... paid circulation in the,period from July 2007 through ... year. This increase was substantially larger than that ... Self, Shape, Health, Martha,Stewart Living and Natural Health., ...
... Provides Financial Guidance for 2008, BIRMINGHAM, Ala., Feb. 20 ... for its fourth quarter and,full year ended December 31, 2007., ... 14.7% decrease from,fourth quarter 2006 revenue of $33.5 million. The ... share. In the fourth quarter of 2006, the,Company earned net ...
... Patients with rheumatoid arthritis are twice as likely ... a doctor about it, according to researchers at the ... Rheumatoid arthritis (RA) the most common form of ... by inflammation of joint tissues, persistent pain, functional disability, ...
... Mouse study suggests it could help control diabetes in humans ... found a way to convert human embryonic stem (ES) cells ... ease a diabetes-like condition in mice, a new study says. ... lead to a renewable source of cells for treatment of ...
... in breast arteries upped chances of cardiovascular trouble, ... In addition to detecting breast cancer in its early ... predict which women are at risk for strokes. , ... -- what doctors call benign arterial calcifications -- were ...
Cached Medicine News:Health News:First Lady Laura Bush Visits AED/Netmark Malaria-Control Project in Ghana 2Health News:Yoga Journal Circulation Increases 5.8 Percent in Second Half of 2007 from Same Period Previous Year 2Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 2Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 3Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 4Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 5Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 6Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 7Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 8Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 9Health News:Doctors should watch for depression in arthritis patients 2Health News:Researchers Make Stem Cells That Secrete Insulin 2Health News:Mammograms Might Spot Stroke Risk 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: